Open AccessAfrican Mitochondrial DNA Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy
Author(s) -
Jeffrey A. Canter,
Gregory K. Robbins,
Doug Selph,
David B. Clifford,
Asha Kallianpur,
Robert W. Shafer,
Shawn Levy,
Deborah G. Murdock,
Marylyn D. Ritchie,
David W. Haas,
Todd Hulgan
Publication year - 2010
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/652419
Subject(s) - mitochondrial dna , antiretroviral therapy , peripheral neuropathy , medicine , virology , mitochondrial toxicity , immunology , human immunodeficiency virus (hiv) , biology , genetics , viral load , diabetes mellitus , endocrinology , gene
Susceptibility to peripheral neuropathy during antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previously associated with a European mitochondrial DNA (mtDNA) haplogroup among non-Hispanic white persons. To determine whether nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy was related to mtDNA variation in non-Hispanic black persons, we sequenced mtDNA of participants from AIDS Clinical Trials Group study 384. Of 156 non-Hispanic black persons with genomic data, 51 (33%) developed peripheral neuropathy. In a multivariate model, African mtDNA subhaplogroup L1c was an independent predictor of peripheral neuropathy (odds ratio, 3.7 [95% confidence interval, 1.1-12.0]). An African mtDNA subhaplogroup is for the first time implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom